Clinical trial · Interventional
Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers
Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers: A Prospective Multicenter Randomized Non-inferiority Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Due to Korean medical crisis, Resident strike, Patient referral (tongue cancer patients) to tertiary center has been in hold. Patient recruitment was seriously affected, and decreased.
Summary
Brief summary (as posted)
A prospective multicenter randomized non-inferiority clinical trial, to evaluate the efficacy and safety of 1.0 cm-safety margin surgery, compared with 1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer Summary: A current standard primary treatment for oral tongue cancer is a curative surgical resection with/without adjuvant radiation treatments (or chemoradiation). In pathological analysis of surgical specimens, more than 5 mm of non-tumorous tissues from the tumor border is regarded as a safe negative resection margin, according to the NCCN guideline (the National Comprehensive Cancer Network, Dec 10. 2020). To achieve this clear margin, surgeons are apt to use a 1.0 to 1.5 cm safety margin around the gross tumor during surgery, considering 30-50% tumor shrinkage in tissue fixation process. Many previous retrospective data have been reported to suggest the optimal or proper surgical extent for oral tongue cancer. Wider resection can lead to better local control, however, it sacrifices more normal tissue, resulting in the functional deficit of tongue (speech and swallowing), even with reconstruction. Unfortunately up to now, no prospective comparison of a different surgical safety margin for oral tongue cancer have been conducted to draw a more solid conclusion. Particularly in early stage oral tongue cancer (cT1-2N0), some study results have suggested that less than 5 mm resection margin in pathology specimens can be also safe and effective in terms of tumor control. To achieve a well-grounded result about the proper surgical safety margin in early stage (cT1-2N0) oral tongue cancer, we will compare the outcomes of the two (1.5 cm versus 1.0 cm) surgical safety margin in curative resection for cT1-2N0 oral tongue cancer.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Resection Margin | — | UNRESOLVED | — |
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Surgery | — | UNRESOLVED | — |
| Tongue Cancer | Malignant Tongue Neoplasm | CURATED_BROADER | 0.80 |
| Tongue Cancer TNM Staging Primary Tumor (T) T1 | — | UNRESOLVED | — |
| Tongue Cancer TNM Staging Primary Tumor (T) T2 | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers | Procedure | — | UNRESOLVED |
| 1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Wide surgical safety margin
- description
- 1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer
- interventionNames
- Procedure: 1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers
- type
- ACTIVE_COMPARATOR
- label
- Narrow surgical safety margin
- description
- 1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer
- interventionNames
- Procedure: 1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers
Primary outcomes (1)
- measure
- 2 year local control rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically proven oral tongue squamous cell carcinoma * Stage cT1-2N0M0 tumors * Treatment-naïve tumor * American Society of Anesthesiologists (ASA) physical status classification 1-3. * Patients who give a written informed consent voluntarily. Exclusion Criteria: * cT3-4 or N(+) tumors * Recurrent tumors or salvage surgery * Patients who have had a previous head and neck surgery and radiation treatment. * Patients who have other head and neck cancer, within the last 5 years.
References
Publications (1)
- BACKGROUNDJang JY, Choi N, Ko YH, Chung MK, Son YI, Baek CH, Baek KH, Jeong HS. Differential Impact of Close Surgical Margin on Local Recurrence According to Primary Tumor Size in Oral Squamous Cell Carcinoma. Ann Surg Oncol. 2017 Jun;24(6):1698-1706. doi: 10.1245/s10434-016-5497-4. Epub 2016 Aug 12. PMID 27519352